About Us

Our Mission

Our mission is to develop therapeutics to treat rare, chronic, and serious infectious diseases in areas of high unmet medical need. As leaders in the field of antimicrobials, we also have both an obligation and a strong desire to combine our drug discovery and development expertise with resources available from public and private organizations to address high unmet needs in global health.


Eric Easom photo

Eric Easom

Co-Founder, President & CEO Director

Sanjay Chanda photo

Sanjay Chanda, PhD

Chief Development Officer

Lucy O. Day photo

Lucy O. Day

Chief Financial Officer

Paul Eckburg photo

Paul Eckburg, MD

Chief Medical Officer

Kevin Krause photo

Kevin Krause, BS, MBA

Chief Strategy Officer

Board of Directors

Joseph S. Zakrzewski

Chair Of The Board Of Directors

Eric Easom

Co-Founder, President & CEO

Kabeer Aziz

Adjuvant Capital, Principal

Rob Readnour

Mountain Group Partners, Managing Director

Lynn Marks, MD

Tunnell Government Services, Vice President

Stephanie Wong

Calithera Biosciences, Chief Financial Officer

Patricia Martin

Biocrossroads, President & CEO


AN2’s founders are an accomplished group of scientific and business leaders in the field of infectious diseases. Their vast knowledge and understanding of boron chemistry and infectious diseases will help guide our plans for the rapid development of treatments for multiple infectious diseases.

Our founders include Eric Easom, President and CEO of AN2 Therapeutics, and a leading infectious diseases expert who recognized the potential of epetraborole and exclusively licensed this asset. Our team also includes George Talbot, MD, Senior Clinical Advisor, Joseph Zakrzewski, Co-Founder and Chair of the Board of Directors, and Dickon Alley, Ph.D., Head of Biology. 

Eric Easom

Co-Founder, President & CEO

Joseph S. Zakrzewski

Chair of The Board of Directors

George H. Talbot, MD, FACP, FIDSA

Co-Founder & Senior Clinical Advisor

Michael R.K. (Dickon) Alley, PhD

Co-Founder & Head of Biology


logo Brii Biosciences

AN2 Therapeutics has a strategic partnership with Brii Biosciences, a clinical-stage company committed to serving patients’ needs and improving public health in China and around the world. The company has licensed rights to Brii Biosciences to develop, manufacture, and commercialize certain compounds, including epetraborole, in China, Hong Kong, Taiwan, and Macau.